Amber Ophthalmics Benefits From Image Reading Center To Develop New Treatment Options For PCED

Lexitas Pharma Services’ unique in-house Reading Center provides Amber with improved visibility, significantly faster communication, and greater control.

About Amber Ophthalmics
Amber Ophthalmics (San Diego, CA, USA) is a clinical stage biopharmaceutical company focused on developing novel therapeutics for rare anterior segment ophthalmic diseases. The company aims to address conditions affecting the ocular surface, and in particular, is focused on providing an innovative treatment option for persistent corneal epithelial defects (PCED).

Over 100,000 patients: the burden of PCED
PCED is an ocular surface sequelae stemming from a variety of underlying conditions, which include, but are not limited to inflammatory disease, autoimmune disease, neurotrophic keratitis, diabetes mellitus, viral eye disease, and chemical and/or thermal injury.

Our Visionary Insights newsletter is published once per quarter and has thousands of subscribers. To keep in touch, subscribe today.